Articles tagged with Statins
The new calculator predicts that over 98% of people eligible for statin treatment are at low risk of serious muscle disorders. The tool aims to support informed treatment decisions by providing personalized risk estimates, helping patients and clinicians weigh benefits and risks.
A study by IR Sant Pau finds that intravenous administration of atorvastatin during myocardial infarction reduces myocardial damage compared to pre-infarction oral loading dose. This results in less necrosis, inflammation and improved cardiac recovery over time.
Researchers found that statin use was associated with a 24% lower risk of developing frailty in older adults. The study suggests that statins may offer an opportunity to reduce the risk of frailty and help people preserve their health and independence as they age.
Prediagnostic statin use showed no association with higher survival rates, but postdiagnostic use was linked to lower all-cause and breast cancer-specific mortality among hormone receptor-positive subtypes. Statin therapy may improve survival of these patient groups.
Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.
A study of 23 large-scale randomised studies found that statins do not cause the majority of side effects listed in package leaflets, including cognitive impairment and depression. The research provided reassurance to patients taking statins, highlighting the benefits of these life-saving drugs outweighing the risks.
A large cohort study found that statins significantly reduce the risk of death and major cardiovascular events in adults with type 2 diabetes. The findings challenge long-standing uncertainty about whether patients at low risk benefit from preventive statin therapy, suggesting that the drugs may have broader protective value.
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
Researchers have identified a key mechanism behind statin-induced muscle damage, paving the way for new statins with reduced side effects. By understanding how statins interact with muscle proteins, scientists can design safer alternatives that preserve cholesterol-lowering benefits.
A recent study found that fewer than half of young adults with severely high cholesterol levels start taking a statin within five years of first high LDL-C measurement. The study highlights significant care gaps in lipid management among adults aged 18-39, particularly those at high risk for premature atherosclerotic cardiovascular dis...
Researchers from FAU's Schmidt College of Medicine recommend using high-potency statins as the primary pharmacologic approach in treating and preventing cardiovascular disease. Lifestyle changes, such as regular physical activity and a healthy diet, are also crucial in reducing cardiovascular risk.
Researchers discovered that statins selectively modulate key components of the Wnt/β-catenin signaling pathway, leading to lower levels of tumor-promoting proteins and cancer-suppressing cellular behaviors. Statins downregulate SATB1 while increasing SATB2, making cancer cells less able to grow and spread.
A large cohort study has shown that supplementary treatment with statins can boost survival chances for critically ill patients with sepsis. The results indicate a 39% lower death rate over 28 days after hospital admission.
A new study from Mass General Brigham found that patients with diabetes who started statin therapy immediately reduced the rate of heart attacks and strokes by one-third compared to those who delayed treatment. The study analyzed data from over 7,000 patients and used artificial intelligence to gather information.
The US Department of Health and Human Services Panel has recommended moderate-intensity statin therapy as the primary prevention among adults with HIV aged 40-75 years with low to intermediate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. For those with a 10-year ASCVD risk score of 5% or higher, statin therapy is strong...
A study of 273,770 individuals with cardiovascular disease found that increasing lipoprotein(a) levels significantly increases the risk of subsequent cardiovascular events. Treatment with high-impact LDL-C lowering therapies may help reduce this risk.
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) taking statin medications at the start of treatment had a significantly lower risk of dying from their cancer. Statin use reduced death rates by 61% compared to non-statin users.
A new study compares prescribing recommendations based on traditional risk factors vs. coronary artery calcium scoring. The study found that patients assessed using the Pooled Cohort Equation had a higher rate of statin medication recommendations than those assessed using the coronary artery calcium score, with 50.7% vs. 22.3% respecti...
A meta-analysis of 14 studies reveals that combination lipid-lowering therapy using statins and ezetimibe significantly lowers LDL cholesterol levels and diminishes cardiovascular risks. Early integration of this approach in treatment protocols can substantially curtail mortality and CVD events.
A large study suggests that patients at high risk of heart attacks and strokes should be treated immediately with a combination of a statin and ezetimibe, rather than statins alone. This combination therapy significantly reduces the risk of death from any cause and major adverse cardiovascular events.
A recent cohort study published in JAMA Internal Medicine found that statin use was associated with a reduced risk of hepatocellular carcinoma and hepatic decompensation in patients with chronic liver disease. This suggests that statins may play a role in preventing the progression of liver disease and reducing the risk of liver cancer.
A new study suggests that statins can reduce chest muscle loss in smokers, while aspirin may contribute to increased muscle loss. The study examined data from 4,191 participants and found that statins protected pectoralis muscle area and density, whereas aspirin led to decreased muscle mass.
A polypill programme combining a statin and three blood pressure lowering drugs could prevent thousands of heart attacks and strokes annually. The approach would be a flagship strategy for disease prevention rather than treatment.
The study found that statin use was associated with reduced 28-day all-cause mortality in critically ill patients. Simvastatin had the highest reduction of mortality among patients in the ICU, particularly in those with chronic obstructive pulmonary disorder, acute kidney injury, sepsis, or myocardial infarction.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
A polypill containing a statin and three half-standard dose antihypertensives could significantly reduce health disparities in low-income, majority Black populations with limited access to healthcare. The study suggests that this treatment approach may be a high-value intervention for preventing cardiovascular disease.
Researchers discovered a potential mechanism behind statin therapy's heart-related benefits in people with HIV. Statin treatment increases the levels of an enzyme called procollagen C-endopeptidases enhancer 1, which helps stabilize vulnerable plaques and prevent their rupture.
A new framework developed by UCLA researchers suggests that genetic data from large libraries of sequenced human genomes can improve the predictive power of genetics in determining how well a patient will respond to commonly prescribed medications and the severity of any side effects. The study, which analyzed data from over 342,000 pe...
A new study published in the Journal of the American Heart Association found that Mexican American women are more likely to miss prescribed doses of stroke prevention medications. The study highlights sex-associated disparities in stroke care, particularly among racial and ethnic minorities.
A study reveals that nearly 137 million US adults are eligible for semaglutide therapy, more than the number eligible for statins. Semaglutide's broad eligibility could lead to increased adoption and treatment options for US adults.
Research suggests statin therapy is cost-effective and beneficial for most over-70s individuals, with increased quality-adjusted life years (QALYs) and reduced healthcare costs. Lifetime use of standard statins increased QALYs by 0.24–0.70, while higher intensity therapy increased QALYs by a further 0.04–0.13.
A recent study published in Gastro Hep Advances found that statin use was associated with a reduced risk of hepatocellular carcinoma (HCC). The research, conducted using data from the All of Us Research Program, suggests that lipophilic statins may be an effective strategy for chemoprevention in HCC. Patients with indications for stati...
Very intensive lipid-lowering therapy significantly regresses atheroma volume at the lesion level compared to statin therapy alone. This study found greater enlargement of the minimum lumen area and more frequent transition to stable plaque phenotypes with alirocumab treatment.
The AHA PREVENT equations could reduce eligibility for statin and antihypertensive therapy among 15.8 million US adults due to lower atherosclerotic cardiovascular disease risk predictions. This change may impact treatment guidelines and recommendations.
A new risk equation could lead to a significant reduction in statin prescriptions, with 28.3 million adults potentially eligible instead of 45.4 million under current guidelines. The PREVENT equations incorporate recent insights into the biology of cardiovascular disease and remove race as a factor.
A study found that statin therapy significantly reduces the risk of cardiovascular disease (CVD) and all-cause mortality in adults aged 60 years and older, including those over 85. Statins also did not increase the risk for adverse events such as myopathies and liver dysfunction.
A study shows post-menopausal women experience a steep rise in heart problems due to reduced estrogen levels, accelerating plaque buildup and cardiovascular risk. Researchers highlight the importance of recognizing early warning signs and increasing screening for coronary artery calcium.
Researchers found that statins altered macrophage response and suppressed inflammatory response in periodontal disease. The study suggests statins could improve gum health and reduce heart disease risk.
Long-term childhood cancer survivors face a significantly higher risk of death from heart-related events compared to the general public. Dyslipidemia and hypertension are key risk factors that should be treated earlier, with statins potentially providing increased protection.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
A new study found that people with Alzheimer's dementia who were treated with lipid-lowering statins showed slower cognitive decline compared to those not treated. The researchers emphasize caution due to the observational nature of the study and initial concerns about statins' effects on patients with dementia.
Researchers found that statin therapy reduced mortality and disease risk among people with chronic kidney disease and frailty, regardless of age-related health conditions. The studies provide additional context to the debate about initiating statin use in people at high risk for heart disease.
According to a new study published in Annals of Internal Medicine, most adults who qualify for statin use for primary prevention are not receiving them. The study found that despite increased overall statin use over time, only 35% of eligible adults were taking statins between 2013 and 2018. The researchers suggest that innovative effo...
A new study suggests that a PCSK9 inhibitor given every 1-3 months may effectively lower bad cholesterol levels in people with non-genetic hypercholesterolemia. The medication, recaticimab, showed similar effectiveness and safety as other PCSK9 inhibitors when administered less frequently.
Researchers analyzed the LODESTAR clinical trial data to compare the long-term effects of rosuvastatin and atorvastatin on adults with coronary artery disease. The study found that both statins were effective in preventing heart attacks, strokes, and death, but rosuvastatin carried a higher risk of developing type 2 diabetes.
A study by Jessica Ho found that Americans born in 2019 can expect to spend 48% and 60% of their lives taking prescription drugs, respectively. The majority of men start taking medication at age 40, while women begin at age 15.
A real-world study confirms the reliability and effectiveness of the Pooled Cohort Equation (PCE) in assessing cardiovascular risk, regardless of statin use. The PCE performed well across different demographics and retained accuracy with measurement factors outside its original risk profile range.
The study found that tenofovir alafenamide fumarate use is associated with a higher incidence of hypertension and statin initiation, particularly among those over 40. Continuous monitoring of blood pressure and lipids for TAF users is recommended.
Research published in the Journal of the American Heart Association found that patients who start taking a combination of statins and ezetimibe after a heart attack are 47% less likely to die within three years. The study suggests that changing treatment guidelines could prevent many thousands of deaths each year.
Researchers at Karolinska Institutet found that statin treatment was associated with a lower risk of developing and dying from colorectal cancer in patients with ulcerative colitis. After a follow-up period of 5.6 years, the study showed that 70 statin users had been diagnosed with colorectal cancer compared to 90 non-statin users.
A new study published in Neurology found that people who take cholesterol-lowering drugs called statins after having a bleeding stroke may have a lower risk of having another stroke, especially ischemic stroke. The study also found no increased risk of bleeding stroke with statin use.
Researchers found that optimized statin therapy can significantly reduce mortality and cardiovascular events in US military veterans with coronary artery disease. Widespread use of ezetimibe alongside statins may lead to additional reductions in cardiovascular risk.
The American College of Physicians recommends starting colorectal cancer screening at age 50 for asymptomatic adults with average risk. The guideline aims to balance benefits and harms of screening in this population. Screening in younger adults may not offer significant net benefit due to lower incidence rates.
The American College of Physicians recommends a federal pandemic preparedness plan, prioritizing health equity and real-time data sharing. ACP also calls for bolstering healthcare supply chains and supporting medical practices during emergencies.
A recent study found that PCSK9 inhibitors may impair lung function in some patients, while statins have a protective effect on the brain, increasing hippocampus volume which may reduce dementia and depression risk. The study used genetic data from 340,000 UK Biobank participants.
A novel molecular pathway has been identified, explaining how a mutation in the ACTA2 gene can cause individuals in their 30s with normal cholesterol levels to develop coronary artery disease. The mutation leads to stress in smooth muscle cells, triggering the production of excess cholesterol and driving atherosclerotic plaque formation.
A new study published in JAMA found that bempedoic acid can reduce major adverse cardiovascular events in high-risk primary prevention patients who cannot tolerate recommended doses of statins. The treatment has the potential to improve outcomes for these patients, providing a new option for primary prevention.
A new study by CNIC researchers reveals that low-grade systemic inflammation triggered by subclinical atherosclerosis accelerates epigenetic aging in otherwise healthy young individuals. The study found a strong association between atherosclerosis progression and accelerated biological age, with potential reversibility through lifestyl...
A new analysis of the CLEAR Outcomes Trial found that bempedoic acid lowered LDL cholesterol levels by 21% and reduced cardiovascular events by 13%. This suggests that different classes of cholesterol drugs have similar benefits for cardiovascular health.
A new study shows that saracatinib reduces inflammation in patients with atherosclerotic cardiovascular disease by more than 90% and boosts genes that help clean up plaque deposits. The experimental cancer drug may offer an effective therapy for cases where standard treatment fails to help.